This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ARIAD Announces Updated Data On AP26113 To Be Presented At The European Cancer Congress 2013 Meeting

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that updated data from its Phase 1/2 trial of AP26113, an investigational inhibitor of anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR) and c-ros oncogene 1 (ROS1), will be presented at the European Cancer Congress (the 38 th ESMO, 32 nd ESTRO, 17 th ECCO) being held in Amsterdam, September 27 to October 1, 2013.

Updated results from the ongoing Phase 1/2 trial will be featured in an oral presentation on Saturday, September 28, 2013. The schedule and meeting location for the session, together with the abstract information, are listed below:

Oral Presentation at ECC 2013
Title:       Updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies
Session: Lung Cancer Localized /Metastatic
Date & Time: Saturday, September 28, 11:15 a.m. (CEST)
Abstract No: 3.401
Presenter: D. Ross Camidge, M.D., Ph.D. (Colorado Cancer Center, Aurora, Colorado)
Location: Elicium 2

About ARIAD

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter ( @ARIADPharm).

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,658.69 -24.89 -0.14%
S&P 500 2,067.75 -1.01 -0.05%
NASDAQ 4,965.1570 -26.7830 -0.54%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs